DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

Post-LOE

dextromethorphan hydrobromide and quinidine sulfate

Hetero

ANDAORALCAPSULE

Approved

Aug 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (dextromethorphan hydrobromide and quinidine sulfate) by Hetero is (dm) is a sigma-1 receptor agonist and an uncompetitive nmda receptor antagonist. Approved for pseudobulbar affect (pba). First approved in 2024.

Drug data last refreshed 22h ago

Mechanism of Action

(DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan…

Indications (1)

pseudobulbar affect (PBA)

Company

Worked on DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.